189 related articles for article (PubMed ID: 35552660)
1. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Coleman IM; DeSarkar N; Morrissey C; Xin L; Roudier MP; Sayar E; Li D; Corey E; Haffner MC; Nelson PS
Clin Cancer Res; 2022 Jul; 28(14):3127-3140. PubMed ID: 35552660
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis.
Liang Y; Rong E; Qian J; Ma C; Hu J
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):327-335. PubMed ID: 35079116
[TBL] [Abstract][Full Text] [Related]
3. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
5. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
[TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
10. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Lundberg A; Zhang M; Aggarwal R; Li H; Zhang L; Foye A; Sjöström M; Chou J; Chang K; Moreno-Rodriguez T; Shrestha R; Baskin A; Zhu X; Weinstein AS; Younger N; Alumkal JJ; Beer TM; Chi KN; Evans CP; Gleave M; Lara PN; Reiter RE; Rettig MB; Witte ON; Wyatt AW; Feng FY; Small EJ; Quigley DA
Cancer Res; 2023 Aug; 83(16):2763-2774. PubMed ID: 37289025
[TBL] [Abstract][Full Text] [Related]
11. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
[TBL] [Abstract][Full Text] [Related]
12. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
14. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
Bianchi S; Mosca A; Dalla Volta A; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Bellissimo AR; Ciccone G; Baier S; Gennari A; Tucci M; Berruti A
Eur J Cancer; 2021 Sep; 155():127-135. PubMed ID: 34371442
[TBL] [Abstract][Full Text] [Related]
15. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB; Liu Y; Hakansson A; Zhao X; Proudfoot JA; Ho J; Zhang JH; Li EV; Karnes RJ; Den RB; Kishan AU; Reiter RE; Hamid AA; Ross AE; Tran PT; Davicioni E; Spratt DE; Attard G; Lotan TL; Lee Kiang Chua M; Sweeney CJ; Schaeffer EM
Cancer; 2023 Jul; 129(14):2169-2178. PubMed ID: 37060201
[TBL] [Abstract][Full Text] [Related]
16. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
17. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
[TBL] [Abstract][Full Text] [Related]
18. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
19. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
20. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
